Quetiapine and Cognitive-Behavior Therapy for Treatment-Resistant Depression
Author Information
Author(s): Chaput Yves, Magnan Annick, Gendron Alain
Primary Institution: McGill University
Hypothesis
The study aims to assess the effectiveness of quetiapine as an adjunct to cognitive-behavior therapy in patients with treatment-resistant depression.
Conclusion
The adjunctive administration of quetiapine to cognitive-behavior therapy may be beneficial for patients with stage II treatment-resistant depression.
Supporting Evidence
- Patients receiving quetiapine showed significant improvement in depression scores compared to those receiving placebo.
- Ten out of eleven patients in the quetiapine group completed the trial, indicating better retention.
- The average reduction in depression scores was about 30% in the quetiapine group.
Takeaway
This study looked at whether adding a medication called quetiapine to therapy helps people who have not gotten better with other treatments for depression. It seems to help some people feel better.
Methodology
Thirty-one patients with treatment-resistant depression underwent a 3-week lithium augmentation followed by randomization to receive either quetiapine or placebo alongside cognitive-behavior therapy.
Potential Biases
Potential bias due to the small number of participants and the nature of the treatment assignment.
Limitations
The study had a small sample size and was preliminary, limiting the generalizability of the results.
Participant Demographics
Patients ranged in age from 23 to 66, with a majority being women (73%).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website